Neurocrine Biosciences, Inc. [NASDAQ: NBIX] price plunged by -18.87 percent to reach at -$28.79.
The one-year NBIX stock forecast points to a potential upside of 27.11. The average equity rating for NBIX stock is currently 1.54, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Neurocrine Biosciences, Inc. [NBIX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NBIX shares is $169.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NBIX stock is a recommendation set at 1.54. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Neurocrine Biosciences, Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 24, 2024. While these analysts kept the previous recommendation, Citigroup raised their target price to Neutral. The new note on the price target was released on December 13, 2023, representing the official price target for Neurocrine Biosciences, Inc. stock. Previously, the target price had yet another raise to $136, while Deutsche Bank analysts kept a Buy rating on NBIX stock. On October 24, 2023, analysts increased their price target for NBIX shares from 135 to 140.
The Average True Range (ATR) for Neurocrine Biosciences, Inc. is set at 5.86, with the Price to Sales ratio for NBIX stock in the period of the last 12 months amounting to 5.90. The Price to Book ratio for the last quarter was 4.98, with the Price to Cash per share for the same quarter was set at 10.29. Price to Free Cash Flow for NBIX in the course of the last twelve months was 25.27 with Quick ratio for the last quarter at 4.08.
NBIX Stock Performance Analysis:
Neurocrine Biosciences, Inc. [NBIX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.98. With this latest performance, NBIX shares dropped by -12.34% in over the last four-week period, additionally sinking by -8.09% over the last 6 months – not to mention a rise of 15.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBIX stock in for the last two-week period is set at 26.29, with the RSI for the last a single of trading hit 19.02, and the three-weeks RSI is set at 31.71 for Neurocrine Biosciences, Inc. [NBIX]. The present Moving Average for the last 50 days of trading for this stock 144.05, while it was recorded at 146.79 for the last single week of trading, and 135.53 for the last 200 days.
Insight into Neurocrine Biosciences, Inc. Fundamentals:
Neurocrine Biosciences, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.08 and a Current Ratio set at 4.19.
NBIX Stock EPS
With the latest financial reports released by the company, Neurocrine Biosciences, Inc. posted 0.82/share EPS, while the average EPS was predicted by analysts to be reported at 0.97/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.15. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBIX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Neurocrine Biosciences, Inc. go to 32.80%.
Neurocrine Biosciences, Inc. [NBIX] Institutonal Ownership Details
There are presently around $96.16%, or 97.11%% of NBIX stock, in the hands of institutional investors. The top three institutional holders of NBIX stocks are: BLACKROCK INC. with ownership of 14.19 million shares, which is approximately 14.2191%. VANGUARD GROUP INC, holding 10.06 million shares of the stock with an approximate value of $$1.38 billion in NBIX stocks shares; and VANGUARD GROUP INC, currently with $$634.43 million in NBIX stock with ownership which is approximately 4.6176%.
